Rituximab biosimilar - Lonza/Teva Pharmaceutical Industries

Drug Profile

Rituximab biosimilar - Lonza/Teva Pharmaceutical Industries

Alternative Names: TL-011

Latest Information Update: 30 Jul 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teva Pharmaceutical Industries - Lonza (JV)
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma; Rheumatoid arthritis

Most Recent Events

  • 25 Jul 2013 Discontinued - Phase-I for Diffuse large B cell lymphoma (combination therapy, first-line therapy) in Hungary, Italy, Latvia, Poland, Russia, Spain, Ukraine, Estonia, Bulgaria and France (IV)
  • 25 Jul 2013 Discontinued - Phase-I/II for Rheumatoid arthritis in Italy and United Kingdom (IV)
  • 25 Jul 2013 Discontinued - Phase-III for Rheumatoid arthritis in Hungary, Poland, Spain, Czech Republic and Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top